Advertisement Continue reading the main story Supported by Continue reading the main story New Therapy for Aggressive Prostate Cancer Improves Survival The experimental treatment relies on radioactive molecules that seek out tumor cells, a strategy that may be useful against other cancers. Prostate cancer is the second-leading cause of cancer death among American men, after… Read More »
Avenda Health, a medtech company based in Santa Monica, California has developed the Focal Therapy System. It provides AI-powered prostate cancer therapy with the aim of treating only tumorous tissues, while reducing side-effects compared with conventional therapies. The system recently received FDA breakthrough designation. At present, there are limited treatment options for men with… Read More »
FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of Rybrevant (amivantamab-vmjw) for the… Read More »
Just a few short months after Johnson & Johnson’s Janssen unit sent its targeted non-small cell lung cancer drug amivantamab to the FDA, the regulator has come back with a green light—a very specific one. Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in… Read More »